EDOCH Alternating With DHAP for New Diagnosed Younger MCL

NCT02858804 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Etoposide
DRUG: Doxorubicin
DRUG: Dexamethasone
DRUG: Vincristine
DRUG: Cyclophosphamide
DRUG: Cytarabine
DRUG: Cisplatin
DRUG: Rituximab
DRUG: Thalidomide
DRUG: Prednisone

Sponsor

Institute of Hematology & Blood Diseases Hospital, China